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Human immunodeﬁciency virus type 1 (HIV-1) coreceptor usage and tropism can be modulated by the
V3 loop sequence of the gp120 exterior envelope glycoprotein. For coreceptors, R5 viruses use CCR5, X4
viruses use CXCR4, and dual-tropic (R5X4) viruses use either CCR5 or CXCR4. To understand the
requirements for dual tropism, we derived and analyzed a dual-tropic variant of an X4 virus. Changes in
the V3 base, which allow gp120 to interact with the tyrosine-sulfated CCR5 N-terminus, and deletion of
residues 310/311 in the V3 tip were necessary for efﬁcient CCR5 binding and utilization. Thus, both sets
of V3 changes allowed CCR5 utilization with retention of the ability to use CXCR4. We also found that
the stable association of gp120 with the trimeric envelope glycoprotein complex in R5X4 viruses, as in
X4 viruses, is less sensitive to V3 loop changes than gp120-trimer association in R5 viruses.
Published by Elsevier Inc.Introduction
The entry of human immunodeﬁciency virus type 1 (HIV-1) into
the host cell is mediated by the viral envelope glycoproteins (Choe
et al., 1998; Wyatt and Sodroski, 1998). The envelope glycoproteins,
gp120 (SU) and gp41 (TM), constitute a trimeric complex that is
anchored on the virion surface by the membrane-spanning segments
of gp41 (Chan et al., 1997; Farzan et al., 1998; Weissenhorn et al.,
1997; Zhu et al., 2003). The mature envelope glycoproteins form a
trimer in which three gp120 subunits are noncovalently bound to
three membrane-anchored gp41 subunits (Helseth et al., 1991). The
initial binding of gp120 to the cellular receptor CD4 triggers con-
formational changes in gp120 that allow the subsequent interaction
with one of the chemokine coreceptors, usually CCR5 or CXCR4Inc.
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ision of Infectious Diseases,
ville, VA 22908.(Alkhatib et al., 1996; Choe et al., 1996; Deng et al., 1996; Doranz
et al., 1996; Dragic et al., 1996; Feng et al., 1996; Wu et al., 1996).
Coreceptor binding is thought to induce additional conformational
changes in the envelope glycoproteins that lead to the fusion of the
viral and target cell membrane (Hoffman and Doms, 1999).
HIV-1 can be classiﬁed into three phenotypes based on the
virus’ ability to use the CCR5 and/or CXCR4 coreceptor (Berger
et al., 1998). R5 viruses use CCR5 as the coreceptor, X4 viruses use
CXCR4 as the coreceptor and R5X4 (dual-tropic) viruses can use
both coreceptors. HIV-1 primarily infects human CD4-positive T
cells and macrophages. Cellular tropism can be determined by
coreceptor usage (Rana et al., 1997). R5 viruses infect primary
macrophages and T lymphocytes, whereas X4 viruses infect
primary T lymphocytes and T-cell lines (Rana et al., 1997). The
coreceptor usage, and thus, cellular tropism, is mainly determined
by the third variable loop (V3 loop) of the gp120 exterior
envelope glycoprotein (Chavda et al., 1994; Chesebro et al.,
1996; Hwang et al., 1991).
The V3 loop of HIV-1 gp120 is about 34–37 residues in length
but exhibits signiﬁcant variability among different isolates
(Hartley et al., 2005). Structurally, the V3 loop can be divided
into three regions: the base, the stem and the tip (crown) (Huang
S.-h. Xiang et al. / Virology 438 (2013) 5–136et al., 2005). The V3 stem is more variable in sequence, whereas
the base and tip are relatively conserved. Because the V3 loop is
the main determinant of coreceptor usage (Chesebro et al., 1996;
Hoffman et al., 2002; Shioda, Levy, and Cheng-Mayer, 1992;
Willey, Theodore, and Martin, 1994), it has been intensively
studied for the purposes of understanding interactions with the
coreceptors and predicting coreceptor usage of HIV-1 isolates. In
general, the V3 loops of X4 viruses have a greater number of
positive charges than those of R5 viruses (Jensen et al., 2003; Low
et al., 2007); however, distinct sequence characteristics have not
been deﬁned for the V3 loops of dual-tropic viruses. Some studies
have shown that residues 306, 321 and 322, the N-linked glycan
at residue 301, and the total number of positive charges in the V3
loop are important for determining coreceptor preference
(Cardozo et al., 2007; de Jong et al., 1992; Fouchier et al., 1995;
Ogert et al., 2001; Polzer et al., 2002). In addition, some bioinfor-
matics tools have been developed to predict coreceptor usage
(Chueca et al., 2009; Jensen et al., 2003). However, the prediction
of coreceptor usage for a given V3 loop based only on the V3
amino acid sequence is still imperfect.
In this report, we explore in more detail the interactions
between the V3 loop sequences and coreceptors CCR5 and CXCR4.
We identify an interesting derivative of the prototypic X4 strain,
HXBc2, that has acquired the ability to use CCR5 but still retains
CXCR4 usage. Two residues in the base of the V3 loop were found
to be critical for this dual-tropic phenotype. Modeling based on
available x-ray crystal and NMR structures and mutagenesis data
suggest that these residues contact the tyrosine-sulfated N-ter-
minus of the chemokine receptor. Another pair of HXBc2 amino
acid residues at the tip of the V3 loop was found to be detrimental
to CCR5 binding and had to be deleted to allow CCR5 tropism. In
addition to analyzing the effects of these changes on HIV-1
tropism, we examined the impact of the V3 changes on envelope
glycoprotein trimer stability and discovered that R5X4 and X4
HIV-1 exhibit similar phenotypes that are distinct from those of
R5 HIV-1.Results
Generation of a dual-tropic HXBc2 variant.
We wished to study the speciﬁc role of certain residues in the
gp120 V3 loop that are important for coreceptor interaction, with
the aim of understanding the mechanism by which some HIV-1
viruses acquire dual tropism. Fig. 1 shows an alignment of the V3
loops of some common X4-, R5-, and dual-tropic viruses. Most
natural HIV-1 isolates lack residues 310–311 (QR in some
laboratory-adapted X4-tropic viruses). Residues 325 and 326
(NM in the laboratory-adapted X4-tropic viruses) are more
commonly DI in primary R5 or R5X4 HIV-1 strains, suggesting
that these residues could be important for CCR5 interaction.
Previous studies have shown the importance of some of theseFig. 1. Sequence alignment of the V3 loops of several common X4-, R5-, and dual-trop
HXBc2 strain, as per current recommendations (Korber et al., 1998). Key V3 residues th
Residues conserved among the V3 loops shown are boxed. A potential N-linked glycosmotifs in virus tropism (Hung et al., 1999); however, the exact
mechanism by which these changes affect viral phenotypes has
not been deﬁned. To investigate the contribution of these residues
to coreceptor choice, we generated HXBc2 mutants containing a
deletion in residues 310–311 (DQR) and/or the changes N325D/
M326I (DI) (Fig. 2A). The infectivity of these V3 loop mutants was
analyzed in Cf2Th cells expressing CD4 and either CXCR4 or CCR5.
Corroborating the hypothesized role of these residues in corecep-
tor usage, we observed that, like the R5-tropic ADA virus and the
dual-tropic 89.6 virus, the DIDQR mutant was able to infect Cf2Th
cells expressing CD4 and CCR5 efﬁciently (Fig. 2B). Surprisingly,
the DIDQR mutant retained the ability to infect CD4/CXCR4 cells
efﬁciently and thus exhibited dual tropism.
To characterize further the contribution of the two V3 ele-
ments to tropism, we generated HXBc2 viruses containing only
the DI substitutions (DI) or the QR deletion (DQR). When these
changes were individually introduced, the resulting mutant
viruses were unable to mediate entry of HIV-1 into CD4/CCR5
cells. In addition, their infectivity in CD4/CXCR4 cells was reduced
compared to that of the wild-type HXBc2 (27% and 68% for the DI
and DQR mutants, respectively) (Fig. 2B). The substitution of an
alanine residue for Arg 311 in the context of the DI mutant (DI/
R311A) abolished the infectivity in CD4/CCR5 and in CD4/CXCR4
cells (Fig. 2B). By contrast, changing Arg 306 to Ser did not alter
coreceptor usage in the context of either HXBc2 or the DI mutant
(Fig. 2B). Together, these data suggest that both the DQR and DI
changes in the V3 region are necessary for the dual-tropic
phenotype.Binding of DIDQR mutants to the 412d antibody and CCR5.
The 412d monoclonal antibody mimics the tyrosine sulfate-
containing N-terminus of the CCR5 coreceptor (Choe et al., 2003;
Huang et al., 2007; Xiang et al., 2005). To assess the binding of the
V3 loop mutants to the 412d antibody, cell supernatants contain-
ing radiolabeled gp120 glycoproteins were immunoprecipitated
with 412d and the bound gp120 was analyzed on an SDS-PAGE
gel. As expected, the wild-type HXBc2 gp120 and the X4 DQR and
R306S mutants did not efﬁciently bind the 412d antibody
(Fig. 2C). However, 412d was able to bind and immunoprecipitate
the R5X4 DIDQR mutant. Surprisingly, 412d also recognized the
DI and DI/R306S mutants (Fig. 2C), even though these two
mutants were not able to infect CD4/CCR5 cells. Similar results
were obtained when the DI change was introduced into the gp120
glycoprotein of another X4 virus, NL4–3 (Fig. 2C). These results
indicate that the DI change, but not the DQR deletion, is required
for 412d antibody binding.
The binding of the V3 loop mutants to CCR5 was also studied.
Supernatants from cells expressing radiolabeled gp120 were
incubated, in the presence of soluble CD4, with cells expressing
CCR5. The bound gp120 glycoprotein was analyzed by SDS-PAGE.
In contrast with the 412d binding results, when we tested the DIic HIV-1 strains. Amino acid position numbering is based on that of the prototypic
at have been previously implicated in coreceptor choice are highlighted with stars.
ylation site at asparagine 301 is indicated by a black oval.
Fig. 2. Sequences and phenotypes of V3 variants of X4 envelope glycoproteins. (A) Sequence alignment of the V3 loops of the HxBc2 and NL4–3 mutants used in this study.
A dot indicates the same residue and a dash a deletion. The potential N-linked glycosylation site at asparagine 301 is labeled with a black oval. (B) Infectivity of HXBc2 V3
loop mutants in cells expressing CD4 and either CXCR4 or CCR5. HIV-1 vectors encoding luciferase and pseudotyped with the indicated envelope glycoproteins were
incubated with cells. Two days later the cells were lysed and assayed for luciferase activity. The results shown are representative of those obtained in three independent
experiments. The values shown are the means of four data points from a single experiment and the error bars represent the standard deviations. (C) Binding of HXBc2 or
NL4–3 gp120 mutants with changes in the V3 loop to the CCR5-mimetic 412d monoclonal antibody. 293T cells expressing the wild-type (wt) or V3 loop mutant HIV-1
envelope glycoproteins were radiolabeled. The cell supernatants were precipitated by the 412d monoclonal antibody. The gp120 glycoproteins precipitated from the media
were analyzed by SDS-PAGE and autoradiography. (D) Binding of wt and mutant gp120 glycoproteins to CCR5. The indicated radiolabeled gp120 envelope glycoproteins
were incubated at room temperature for 1 h with Cf2Th-CCR5 cells in the presence of sCD4. The cells were washed and lysed, and the bound gp120 was precipitated by a
mixture of sera from HIV-1-infected individuals. The bound gp120 glycoprotein was analyzed by SDS-PAGE and autoradiography.
Fig. 3. Syncytium-forming activity of HIV-1 envelope glycoprotein variants. 293T
cells expressing the indicated HIV-1 envelope glycoproteins were cocultivated
with Cf2Th-CD4/CCR5 cells and syncytium formation measured as described in
Materials and methods. The values shown are the means of six data points from a
single representative experiment and the error bars represent the standard
deviations.
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that the DI change alone was not sufﬁcient to allow binding to
CCR5 (data not shown); only the DIDQR mutant was able to bind
CCR5 detectably (Fig. 2D). Apparently, the DI change is sufﬁcient
to allow binding to 412d and perhaps, by analogy, with the
tyrosine-sulfated CCR5 N-terminus; however, other changes,
speciﬁcally the removal of the QR residues in the V3 tip, are
required for binding to the intact CCR5 coreceptor. These binding
results explain why only the DIDQR mutant, but not the DI
mutant, is able to infect CD4/CCR5-expressing cells.
Membrane fusion ability of the DIDQR mutant.
The ability of the V3 loop mutants to mediate the fusion of
envelope glycoprotein-expressing cells and cells bearing CD4 and
either CCR5 or CXCR4 was assessed using the a-complementation
assay (Holland et al., 2004). 293 T cells were cotransfected with
plasmids expressing the mutant envelope glycoproteins and the
a-fragment of b-galactosidase. The cotransfected 293 T cells were
cocultivated with canine Cf2Th cells expressing CD4, one of the
coreceptors CCR5 or CXCR4, and the o fragment of b-galactosi-
dase. The fusion of the envelope-expressing 293 T cells with the
Cf2Th cells expressing HIV-1 receptors results in the reconstitu-
tion of enzymatically active b-galactosidase. The measurement of
S.-h. Xiang et al. / Virology 438 (2013) 5–138b-galactosidase activity provides a quantiﬁcation of the extent of
the fusion. The membrane fusion data (Fig. 3) showed that all the
mutants assayed, DI, DQR, R306S, DI/R306S and DIDQR, retained
the ability to fuse with CD4/CXCR4-expressing cells at levels
comparable to that of the wild-type HXBc2 envelope glycopro-
teins. Only the DIDQR mutant gained the ability to fuse with CD4/
CCR5-expressing cells at levels comparable to that of the envelope
glycoproteins of the dual-tropic virus 89.6. Thus, the results of the
cell–cell fusion assay agree with the infectivity and CCR5 binding
data (Fig. 2).The DI motif in the C-terminal region of the V3 loop is necessary
for CCR5 usage.
The above results indicated that, in the context of HXBc2
envelope glycoprotein, the DI motif (residues 325–326) in the C-
terminal segment of the V3 loop is important for CCR5 usage and
binding (Fig. 2B and D), as well as sufﬁcient for 412d binding
(Fig. 2C). Thus, we further dissected this motif by making single
alanine substitutions in residues 325 and 326 of the DIDQR
mutant (Fig. 2A). The binding of the resulting mutants, DIDQR
D325A and DIDQR I326A, to the 412d antibody was signiﬁcantly
reduced or abolished, respectively (Fig. 4A). We also tested the
binding of these mutants to a mixture of polyclonal sera from
HIV-1-infected individuals and monoclonal antibodies E51, a
CD4-induced antibody, and F425b, an antibody that speciﬁcally
binds to the V3 loop of R5 viruses (Cavacini et al., 2003; Xiang
et al., 2003). The 412d and F425b antibodies precipitated the R5Fig. 4. Phenotypes of HXBc2 DIDQR envelope glycoproteins with changes in the V3
expressing wild-type (wt) or V3 loop mutant HIV-1 envelope glycoproteins were radio
infected individuals (PS) or by the indicated monoclonal antibody. The gp120 glycoprote
(B) Processing and subunit association of HIV-1 envelope glycoprotein V3 loop mutant
indicated HIV-1 strains were radiolabeled. The cells were pelleted and lysed. The radio
infected individuals. The envelope glycoproteins precipitated from the cell lysates and
are indicated. (C) Infectivity of HXBc2 V3 loop mutants in cells expressing CD4 and eit
indicated envelope glycoproteins were incubated with cells. Two days later the cells we
those obtained in two independent experiments. The values shown are the means of fo
deviations.ADA gp120 but not the X4 HXBc2 gp120, as expected. Both DIDQR
mutants were recognized by the E51 and F425b antibodies; the
DIDQR D325A and DIDQR I326A mutants were precipitated
slightly less efﬁciently than DIDQR by the E51 antibody
(Fig. 4A). Both mutant envelope glycoproteins were processed at
levels comparable to wild-type HXBc2 and ADA envelopes
(Fig. 4B). The ratio of gp120 shed into the medium relative to
the cell-associated gp120 was similar to that of the wild-type
glycoproteins for all the mutants (Fig. 4B). These results together
indicate that the reduced binding to 412d was not due to a global
misfolding of the mutant envelope glycoproteins, and that aspar-
tic acid 325 and isoleucine 326 are important for the recognition
of gp120 by the 412d antibody.
The infectivity of the D325A and I326A mutants was assessed in
Cf2Th cell lines expressing the HIV-1 receptors. Bothmutants infected
CD4/CXCR4 cells efﬁciently (Fig. 4C), suggesting that these mutant
envelope glycoproteins are properly folded and functional for CXCR4
binding. However, the D325A and I326A changes resulted in a loss of
the ability of the DIDQR mutant to infect CD4/CCR5 cells (Fig. 4C).
These results support the importance of the DI motif for CCR5
coreceptor usage, but not for CXCR4 usage.Asparagine 302 in the V3 N-terminus contributes to CCR5 binding
In the N-terminal segment of the V3 loop there is a motif of
three asparagines (NNN) that is relatively well conserved among
most HIV-1 strains (Fig. 1). This motif lies in the base of the V3
loop in close proximity to residues 325–326 (Huang et al., 2007;base. (A) Binding of ligands to HIV-1 envelope glycoprotein variants. 293T cells
labeled. The cell supernatants were precipitated by a mixture of sera from HIV-1-
ins precipitated from the media were analyzed by SDS-PAGE and autoradiography.
s. 293T cells expressing wild-type (wt) or mutant envelope glycoproteins from the
labeled cell lysates and media were precipitated by a mixture of sera from HIV-1-
media were analyzed by SDS-PAGE. The gp160 and gp120 envelope glycoproteins
her CXCR4 or CCR5. HIV-1 vectors encoding luciferase and pseudotyped with the
re lysed and assayed for luciferase activity. The results shown are representative of
ur data points from a single experiment and the error bars represent the standard
S.-h. Xiang et al. / Virology 438 (2013) 5–13 9Schnur et al., 2011). We investigated the importance of this region
to CCR5 and CXCR4 usage by changing Asn 302 to aspartic acid;
this change does not delete the potential N-linked glycosylation
site at Asn 301. Introduction of an N302D change in the context of
the DIDQR envelope glycoprotein drastically reduced the binding
of gp120 to the 412d antibody (Fig. 4A), as was seen for the
D325A and I326A mutants. The DIDQR N302D mutant was
recognized efﬁciently by the E51 and F425b monoclonal anti-
bodies. To conﬁrm whether the N302D change would affect the
coreceptor usage of the DIDQR virus, we tested the ability of this
mutant to infect cells expressing CD4 and either CCR5 or CXCR4.
The expression, processing and subunit association of the DIDQR
N302D mutant were comparable to those of the wild-type HXBc2
envelope glycoproteins and the DIDQR mutant (Fig. 4B). However,
the N302D change abolished the ability of the DIDQR envelope
glycoproteins to infect CD4/CCR5 cells (Fig. 4C) and reduced by
about 3-fold the infection of CD4/CXCR4 cells. Thus, the relatively
conservative substitution of aspartic acid for asparagine 302
resulted in disruption of CCR5 usage.
Changes in the V3 N-terminus of primary virus envelope
glycoproteins
To investigate the Asn-rich region in the N-terminus of the gp120
V3 region of natural R5 or R5X4 viruses, we introduced changes in
residues Asn 300 and Asn 302 of the YU2 (R5) and 89.6 (R5X4)
envelope glycoproteins (Fig. 5A). Asn 301 is an N-linked glycosylation
site and the elimination of this glycan could signiﬁcantly modify the
conformation of this region, so this residue was not altered. The
introduction of the changes, N300D and N302D, alone or in combina-
tion, in the dual-tropic 89.6 strain eliminated its infectivity in Cf2Th
cells expressing CD4 and CCR5 or CD4 and CXCR4 (Fig. 5B). Similarly,
these changes also eliminated the infectivity of viruses with the YU2
envelope glycoproteins in Cf2Th cells expressing CD4 and CCR5
(Fig. 5B). To examinewhether these changesmight affect the integrity
of the envelope glycoproteins, we examined the binding of these
mutants to several molecules (Fig. 5C). Binding of all the mutants to
CD4-Ig and the E51 antibody was efﬁcient and comparable to that of
wild-type 89.6 and YU2 gp120; however, the binding of mutants
N302D and N300D/N302D to the 412d antibody and CCR5 was
drastically reduced, which may have contributed to the lack of
infectivity of these mutants in CD4/CCR5 cells. The N300D change
did not affect the binding to the 412d antibody for the gp120
glycoprotein of either strain. This change signiﬁcantly reduced the
binding of 89.6 gp120 to CCR5, helping to explain the lack of
infectivity of this mutant. The YU2 N300D mutant efﬁciently binds
CCR5 (Fig. 5C), even though it does not support infection of CD4/CCR5
cells (Fig. 5B). These results suggested that different mechanisms
might contribute to the loss of infectivity of the 89.6 and YU2
mutants. To investigate this possibility, we studied the expression,
processing and subunit association of these envelope glycoproteins.
Although the expression levels and processing of the mutants were
comparable to those of the wild-type envelope glycoproteins, all the
YU2 mutants exhibited dramatic shedding of gp120 into the medium
(Fig. 5D). By contrast, the expression, processing and subunit associa-
tion of the 89.6 mutants were comparable to those of the wild-type
envelope glycoproteins. These data suggest that the lack of infectivity
of the N300D and N302D YU2 mutants is due to the instability of
gp120 association with the envelope glycoprotein trimer rather than
an effect on CCR5 binding ability.Discussion
Many previous studies have demonstrated the role of the HIV-
1 gp120 V3 loop in coreceptor binding and determination of R5 orX4 tropism (Cardozo et al., 2007; Foda et al., 2001; Maeda et al.,
2008a; Sander et al., 2007; Svicher et al., Perno; Verrier et al.,
1999; Xiao et al., 1998). Here, we addressed how a single V3
structure in a dual-tropic virus meets the requirements to
recognize the CCR5 and CXCR4 coreceptors. By systematically
studying the contribution of V3 loop changes to the generation of
an R5X4 variant, DIDQR, from the prototypical X4 virus HXBc2,
we can suggest a reasonable mechanistic model for dual tropism.
First, our studies underscore the critical importance of sequences
in the base of the V3 loop for coreceptor binding. The N-terminus
and C-terminus of the V3 loop, which constitute the V3 base, are
quite conserved among X4 and R5 viruses. However, our results
show that the DI motif at residues 325 and 326 in the C-terminal
region of the V3 loop is important for CCR5 utilization as well as
for binding to the 412d antibody, but plays a less important role
in CXCR4 usage. The heavy chain complementarity-determining
region (CDR) loop of the 412 antibody has sulfate-modiﬁed
tyrosine residues that mimic the CCR5 N-terminus (Choe et al.,
2003; Dorfman et al., 2006; Huang et al., 2007; Xiang et al., 2005).
For example, it has been shown that these 412d sequences can
functionally replace the CCR5 N-terminus to allow coreceptor
function for R5 HIV-1 entry (Xiang et al., 2005). These results
suggest that Asp 325 and Ile 326 might be directly interacting
with CCR5, but not with CXCR4. Although the full structure of
CCR5 has not been solved, the NMR structure of a CCR5 N-
terminal peptide in the presence or absence of gp120 has been
determined and provides some insight into the interactions
between gp120 and the N-terminus of CCR5 (Huang et al., 2007;
Schnur et al., 2011). The docking model of gp120 and the CCR5 N-
terminal peptide (Fig. 6A) predicts speciﬁc interactions between
the N-terminus of CCR5 and the base of the gp120 V3 loop. In this
model, gp120 residues Asn 302, Asp 325 and Ile 326 interact with
Asn 13 and the key sulfated Tyr 10 and Tyr 14 residues in the
CCR5 N-terminus. In the crystal structure of the HIV-1 gp120 core
in complex with CD4 and the Fab fragment of the CCR5-mimetic
412d antibody, the 412d antibody makes similar contacts with
the gp120 V3 loop (Huang et al., 2007). The CDR3 loop of the 412d
antibody heavy chain crosses over the base of the gp120 V3 loop
and the sulfated tyrosines Tys 100 and Tys 100c of 412d closely
interact with gp120 residues N302, D325 and I326 (Fig. 6B).
Antibody 412d, however, interacts with a much larger overall
surface of gp120 than the CCR5 N-terminal peptide (Huang et al.,
2007). The additional contacts made by the 412d antibody with
gp120 residues conserved among R5 and X4 viruses helps to
explain why the HXBc2 DI mutant efﬁciently bound the 412d
antibody but not CCR5, and thus was unable to infect CD4/
CCR5 cells.
Second, our results suggest that additional interactions besides
those involving the base of the gp120 V3 loop are necessary for
competent CCR5 attachment. When Gln 310 and Arg 311 were
deleted from the V3 tip of the DI mutant, the resulting DIDQR
mutant gained the ability to use CCR5, exhibiting a typical dual-
tropic phenotype. The deletion of residues 310 and 311 was
necessary but not sufﬁcient for CCR5 binding and R5 tropism.
Apparently, the presence of Gln 310 and Arg 311 interferes with
the interaction of gp120 with CCR5. Previous studies have
suggested that the tip of the V3 loop may contact the second
and third extracellular loops (ECL2 and ECL3) of the coreceptors
(Chabot and Broder, 2000; Maeda et al., 2008b; Samson et al.,
1997; Wu et al., 1997; Zhang et al., 2007). The proposed two-
point contact involving the base and tip of the gp120 V3 loop with
the CCR5 N-terminus and extracellular loops, respectively,
implies that the length and spatial geometry of the V3 loop are
both important for efﬁcient CCR5 binding. The QR insertion in the
V3 tip could conceivably alter either of these V3 parameters,
disrupting the interaction with CCR5. CCR5 and CXCR4 usage
Fig. 5. Effects of changes in the V3 base of primary HIV-1 envelope glycoproteins. (A) Sequence alignment of the V3 loops of the YU2 and 89.6 envelope glycoprotein
mutants used in this study. A dot indicates the same residue, and a dash indicates a deletion. (B) Infectivity of YU2 or 89.6 V3 loop mutants in cells expressing CD4 and
either CXCR4 or CCR5. HIV-1 vectors encoding luciferase and pseudotyped with the indicated envelope glycoproteins were incubated with cells. Two days later the cells
were lysed and assayed for luciferase activity. The results shown are representative of those obtained in two independent experiments. The values shown are the means of
four data points from a single experiment and the error bars represent the standard deviations. (C) Binding of ligands to HIV-1 envelope glycoprotein variants (previously
presented as Supporting Fig. S10 in Huang et al. (2007)). 293T cells expressing the wild-type (wt) or indicated V3 loop mutant HIV-1 envelope glycoproteins were
radiolabeled. The cell supernatants were precipitated by a mixture of sera from HIV-1-infected individuals (PS), by CD4-Ig, or by the indicated monoclonal antibody. For
some of the precipitations by the 412d antibody, the gp120-containing cell supernatants were incubated with sCD4 (ﬁnal concentration 200 nM). The gp120 glycoproteins
precipitated from the media were analyzed by SDS-PAGE and autoradiography. For the measurement of CCR5 binding, the indicated radiolabeled gp120 envelope
glycoproteins were incubated at room temperature for 1 h with Cf2Th-CCR5 cells in the presence of sCD4 (200 nM). The cells were washed and lysed, and the bound gp120
was precipitated by a mixture of sera from HIV-1-infected individuals. The bound gp120 glycoprotein was analyzed by SDS-PAGE and autoradiography. (D) Processing and
subunit association of HIV-1 envelope glycoprotein V3 loop mutants. 293T cells expressing the wild-type (wt) or mutant envelope glycoproteins from the indicated HIV-1
strains were radiolabeled. The cells were pelleted and lysed. The radiolabeled cell lysates and media were precipitated by a mixture of sera from HIV-1-infected
individuals. The envelope glycoproteins precipitated from the cell lysates and media were analyzed by SDS-PAGE. The gp160 and gp120 envelope glycoproteins are
indicated.
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tropism, residues 302, 325 and 326 in the V3 base, residues in the V3
tip, and the length and orientation of the V3 loop are important; for
X4 tropism, other residues like 306, 321 and 322, as previously
reported (Cardozo et al., 2007), appear to be important.
Our previous studies (Xiang et al., 2010) have shown that
changes in the length or orientation of the V3 loop can disrupt the
stability of the HIV-1 envelope glycoprotein trimer. We showed
that single amino acid insertions in the V3 loop can destabilize
the envelope glycoprotein trimer, and that the envelope glyco-
proteins of R5 viruses are more sensitive than those of X4 viruses
to these insertions (Xiang et al., 2010). Some of the alterations of
the V3 loop studied here affected the stability of the envelopeglycoprotein trimer, resulting in shedding of gp120 and loss of
infectivity. The impact of some V3 changes on envelope glyco-
protein trimer stability differed in R5, X4 and R5X4 viruses. For
example, the N302D change resulted in gp120 shedding in the
envelope glycoproteins of the R5 YU2 isolate, but not in the
envelope glycoproteins of the X4 HXBc2 or R5X4 89.6 isolates. In
our previous study (Xiang et al., 2010), insertions in the V3 loop of
the X4 HXBc2 isolate did not induce shedding of gp120, whereas
the same V3 changes in R5 isolates did. Our results indicate that
R5X4 Envs (89.6 or HXBc2 DIDQR) resemble X4 Envs with respect
to the induction of gp120 shedding by V3 changes. Together, the
data indicate that R5 isolates are more prone to the shedding of
gp120 as a result of the introduction of changes in the V3 loop. In
Fig. 6. Models of the interactions of the V3 loop with CCR5 and the 412d antibody.
The interactions of the CCR5 N-terminal domain (A) or the 412d antibody (B) with
the V3 loop of the HIV-1 gp120 envelope glycoprotein were modeled. Residues
302, 325 and 326 in the base of the gp120 V3 loop and their interaction with the
CCR5 N-terminal peptide (A) and the 412d antibody (B) are shown. The models are
based on the NMR structure of CCR5215 (PDB ID: 2RLL) and the x-ray crystal
structure of the gp120-412d-CD4 complex (PDB ID: 2QAD) (Huang et al., 2007).
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has been suggested to project towards the trimer axis (Mao et al.,
2012; Xiang et al., 2010). The V3 loops of R5 viruses may be
accommodated differently in the envelope glycoprotein struc-
tures that abut the trimer axis than the V3 loops of X4 and dual-
tropic viruses.
Our results add to an understanding of the gp120 V3 loop
determinants that dictate coreceptor usage, and provide mechan-
istic insights into the particular V3 changes involved in the shift
from mono tropism to dual tropism. This understanding may
assist attempts to block the interaction of HIV-1 with its
coreceptors.Materials and methods
HIV-1 envelope glycoprotein V3 loop mutants
Mutations were introduced into the pSVIIIenv plasmid expres-
sing the full-length envelope glycoproteins from the HXBc2 HIV-1strain (Sullivan et al., 1995), using the QuikChange II XL site-
directed mutagenesis protocol (Stratagene). The presence of the
desired mutations was conﬁrmed by DNA sequencing. The gp120
substitution mutants are designated with the amino acid residue
to the right of the number substituted for the amino acid residue
to the left of the number. All residues are numbered according to
those of the prototypic HXBc2 sequence, as per current conven-
tion (Korber et al., 1998).
Syncytium formation assay
The ability of the HIV-1 envelope glycoprotein variants to
mediate cell–cell fusion was determined by the a-complementa-
tion assay (Holland et al., 2004). In this assay, the N-terminal (a)
fragment of b-galactosidase is coexpressed with the HIV-1 envel-
ope glycoproteins; the C-terminal (o) fragment of b-galactosidase
is expressed in the receptor-bearing target cells. Upon fusion of
the envelope glycoprotein-expressing cells and the target cells,
the b-galactosidase is reconstituted, and its activity can be
measured. The assay was performed as previously described
(Xiang et al., 2010). Brieﬂy, 293 T cells in six-well plates were
transfected with plasmids expressing the b-galactosidase a frag-
ment, the HIV-1 envelope glycoproteins and the HIV-1 Tat protein
in a 4:4:1 weight ratio. Cf2Th-CD4/CCR5 cells or Cf2Th-CD4/
CXCR4 cells in 100-mm dishes were transfected with 3 mg of a
plasmid expressing the b-galactosidase o fragment. On the next
day, the Cf2Th target cells were lifted from the plates with 5 mM
EDTA in phosphate-buffered saline (EDTA-PBS) and reseeded at
105 cells/well in 96-well plates. One day later, the transfected
293 T cells were lifted from the plates with 5 mM EDTA-PBS and
diluted to 2105 cells/ml with Dulbecco’s modiﬁed Eagle’s med-
ium supplemented with 10% fetal bovine serum (DMEM-10).
Approximately 2104 293 T cells (in 100 ml) expressing the
HIV-1 envelope glycoproteins were added in triplicate to each
well of a 96-well plate containing the target cells. The coculti-
vated cells were cultured at 37 1C in a CO2 incubator for 4 h. The
medium was then removed, and the cells were washed once with
PBS and lysed in 20 ml of lysis buffer. The plate was covered with
Paraﬁlm, wrapped in plastic ﬁlm and placed at 70 1C for 30 min.
The b-galactosidase activity was measured with a Galacto-Star b-
galactosidase reporter gene assay system for mammalian cells
(Tropix, Bedford, MA), using a Berthold Microplate Luminometer
LB 96 V (Promega).
Infection by single round luciferase-expressing HIV-1
Envelope complementation assays were performed using HIV-
1 viruses capable of only a single round of infection, as described
previously (Pacheco et al., 2008). Brieﬂy, recombinant luciferase-
expressing HIV-1 viruses (Helseth et al., 1990) were generated by
transfecting 293 T cells with the pSVIIIenv plasmid expressing the
HIV-1 envelope glycoproteins of interest, the pCMVDP1DenvpA
packaging plasmid, and an HIV-1 vector plasmid at a 1:1:3 ratio,
using the calcium phosphate transfection method (Invitrogen).
The HIV-1 vector plasmid expresses an RNA that can be packaged
into virions, reverse transcribed, and integrated into a target cell,
where it encodes ﬁreﬂy luciferase. Forty-eight hours after trans-
fection, supernatants containing reporter viruses were harvested
and cleared by low-speed centrifugation. The amounts of virus in
the supernatants were assessed by measurement of reverse
transcriptase (RT) (Rho et al., 1981). For infection, Cf2Th-CD4/
CCR5 or Cf2Th-CD4/CXCR4 cells were seeded at a density of 6000
cells/well in 96-well luminometer-compatible tissue culture
plates. The following day, the cells were incubated with 2500
RT units of recombinant virus per well. Two days later, the cells
were lysed with 30 ml of passive lysis buffer (Promega), and the
S.-h. Xiang et al. / Virology 438 (2013) 5–1312luciferase activity measured in the Berthold microplate lumin-
ometer LB 96 V (Promega).
Immunoprecipitation of HIV-1 envelope glycoproteins
293 T cells were transfected with pSVIIIenv plasmids expres-
sing the HIV-1 envelope glycoproteins and a plasmid expressing
the HIV-1 Tat protein. One day later, the cells were metabolically
labeled for 16 h with 100 mCi/ml of [35S]-methionine/cysteine
([35S] protein labeling mix; Perkin-Elmer) in Dulbecco’s modiﬁed
Eagle’s medium lacking methionine and cysteine and supplemen-
ted with 5% dialyzed fetal bovine serum. The cell lysates (contain-
ing gp160 and gp120) and media (containing gp120) were used
for immunoprecipitation. Brieﬂy, 100 ml of clariﬁed cell lysate or
medium was incubated with 100 ml of 10% protein A-Sepharose
beads (Amersham Biosciences), 50 ml of 4% bovine serum albu-
min, and 1 mg of monoclonal antibody with or without sCD4
(10 mg/ml) or, instead of the monoclonal antibody, 4 ml of a
mixture of sera from HIV-1-infected individuals. The mixtures
were brought to a volume of 1 ml with PBS and incubated on a
shaking platform at room temperature for 1 h. The pelleted beads
were washed twice with 0.5 M NaCl-PBS and once with PBS. The
beads were then suspended in a 2 gel-loading buffer, and boiled
for 3 min. Following the removal of the beads by centrifugation,
the supernatants were loaded on a 10% SDS-polyacrylamide gel.
The gel was ﬁxed, dried at 80 1C for 2 h and exposed to X-ray ﬁlm.
CCR5 binding assay
To assess CCR5 binding ability, normalized amounts of radi-
olabeled gp120 envelope glycoproteins from transfected 293 T-
cell supernatants were incubated with an excess of sCD4 and
Cf2Th-CCR5 cells, as previously described (Xiang et al., 2010).
Brieﬂy, Cf2Th-CCR5 cells were lifted from the plate by using 5 mM
EDTA-PBS (pH 7.5). After a wash with DMEM, the cells were
resuspended in DMEM and added to 1.5-ml microcentrifuge tubes
(106 cells/tube). The radiolabeled gp120-containing cell super-
natants (400 ml) and 10 mg of sCD4 were added to the tube, and
the volume was adjusted to 1 ml with DMEM. The tubes were
rocked at room temperature for 1 h. The cells were then washed
once with PBS and lysed in 1 ml of buffer containing 1% NP-40.
The cell lysates were precipitated with a mixture of sera from
HIV-1-infected individuals and protein A-Sepharose beads (Amer-
sham Biosciences) at 4 1C for 2 h. The precipitated gp120 was
analyzed by SDS-PAGE and autoradiography.Acknowledgments
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